3/19
06:20 am
sln
Silence Therapeutics (SLN) was upgraded by Jefferies Financial Group Inc. to "strong-buy".
Low
Report
Silence Therapeutics (SLN) was upgraded by Jefferies Financial Group Inc. to "strong-buy".
3/5
05:20 pm
sln
Silence Therapeutics GAAP EPS of -$0.63, revenue of $0.5M [Seeking Alpha]
High
Report
Silence Therapeutics GAAP EPS of -$0.63, revenue of $0.5M [Seeking Alpha]
3/5
01:08 pm
sln
Silence Therapeutics (SLN) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Medium
Report
Silence Therapeutics (SLN) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/5
07:30 am
sln
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
3/2
09:02 pm
sln
Silence Therapeutics (SLN) had its "outperform" rating reaffirmed by William Blair.
Medium
Report
Silence Therapeutics (SLN) had its "outperform" rating reaffirmed by William Blair.